Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Judith Everts-Graber"'
Autor:
Judith Everts‐Graber, Harald Bonel, Daniel Lehmann, Brigitta Gahl, HansJörg Häuselmann, Ueli Studer, Hans‐Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Publikováno v:
JBMR Plus, Vol 6, Iss 10, Pp n/a-n/a (2022)
ABSTRACT Atypical femoral fractures (AFFs) have been reported in patients taking bisphosphonates (BPs) for osteoporosis therapy but also in patients with no exposure to these drugs. In contrast, less is known about the incidence of AFFs in patients t
Externí odkaz:
https://doaj.org/article/9f37930ae40e41d384d36a6396d111cd
Publikováno v:
Bulletin des Médecins Suisses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7d6243b6d8fca25fe7e7900cea43701
https://doi.org/10.4414/bms.2023.21594
https://doi.org/10.4414/bms.2023.21594
Publikováno v:
Schweizerische Ärztezeitung.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ee4572421faa02f2d7d9795ffa94b23
https://doi.org/10.4414/saez.2023.21594
https://doi.org/10.4414/saez.2023.21594
Autor:
Judith Everts-Graber, Stephan Reichenbach, Brigitta Gahl, HansJörg Häuselmann, Hans-Rudolf Ziswiler, Ueli Studer, Thomas Lehmann
BACKGROUND The rebound effect after denosumab discontinuation is lessened with subsequent zoledronate therapy. However, it is unclear whether this mitigation is sufficient after long-term denosumab treatment. OBJECTIVE This retrospective observationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d79ca74a0c7f3009c3aed625b408071
Autor:
Judith Everts-Graber, Thomas Lehmann
Publikováno v:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 25(3)
Denosumab discontinuation can lead to bone loss despite subsequent bisphosphonate therapy. This bone loss is more severe in patients treated with denosumab for longer than 3 years. We aimed to evaluate the bone mass changes after only a single denosu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731a2499274635b03a95e734c2b9db17
https://pubmed.ncbi.nlm.nih.gov/35450795
https://pubmed.ncbi.nlm.nih.gov/35450795
Autor:
Judith Everts-Graber, Ueli Studer, Thomas Lehmann, John-Patrik Burkard, H J Hauselmann, Stephan Reichenbach, Daniel Lehmann, Brigitta Gahl, Benoit Schaller, Hans-Rudolf Ziswiler
Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b136e7ab9c455f4fab998a8ed4157e
Autor:
Ueli Studer, Stephan Reichenbach, Hans-Rudolf Ziswiler, Brigitta Gahl, Judith Everts-Graber, Thomas Lehmann
Publikováno v:
Bone. 144
Background Denosumab discontinuation without subsequent bisphosphonates (BPs) is associated with bone loss and multiple vertebral fractures. Objective Identifying risk factors for bone loss and vertebral fractures after denosumab discontinuation. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee1bf03d00cd99b3a665c0f83114aea
https://pubmed.ncbi.nlm.nih.gov/33359006
https://pubmed.ncbi.nlm.nih.gov/33359006
Autor:
Jacqueline Aston, Martina Papmeyer, Rolf-Dieter Stieglitz, Judith Everts-Graber, Stefan Borgwardt, Anita Riecher-Rössler, Ulrike Heitz, Erich Studerus
Publikováno v:
Early Intervention in Psychiatry. 12:907-914
Aim: We aimed to determine the prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP) in terms of specificity, sensitivity, positive and negative predictive value by following up individuals that were initially not considered to b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25df53c0aaa46fd541fbe563c2bb05b7
https://doi.org/10.1111/eip.12401
https://doi.org/10.1111/eip.12401
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchReferences. 35(7)
Discontinuation of denosumab is associated with a rapid return of bone mineral density (BMD) to baseline and an increased risk of multiple vertebral fractures. No subsequent treatment regimen has yet been established for preventing either loss of BMD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47fbe2bd88ce83994c4bc453aced57ed
https://pubmed.ncbi.nlm.nih.gov/32315077
https://pubmed.ncbi.nlm.nih.gov/32315077
Autor:
Judith Everts-Graber, Y. Li, Burkhard Möller, Axel Finckh, Stefan Florentinus, Hartmut Kupper
Publikováno v:
Arthritis Care and Research, Vol. 70, No 6 (2018) pp. 861-868
Objective To study low blood hemoglobin concentrations as a predictor of radiographic damage progression in patients with rheumatoid arthritis (RA). Methods Post-hoc analyses were performed in patients from the PREMIER trial with early RA undergoing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfbed634a374379ee137547b51a78c29
https://pubmed.ncbi.nlm.nih.gov/28950430
https://pubmed.ncbi.nlm.nih.gov/28950430